Molecular Characterization of Carbapenem-Resistant *Serratia marcescens* Clinical Isolates in a Tertiary Hospital in Hangzhou, China

This article was published in the following Dove Press journal:
Infection and Drug Resistance

Qian Xu¹
Ying Fu²
Feng Zhao²
Yan Jiang¹
Yunsong Yu¹

¹Department of Infectious Diseases, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Key Laboratory of Microbial Technology and Bioinformatics of Zhejiang Province, Hangzhou City, Zhejiang Province, 310016, People's Republic of China;
²Clinical Laboratory, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou City, Zhejiang Province 310016, People's Republic of China

Introduction: Although carbapenem-resistant Enterobacteriaceae (CRE) have been thoroughly investigated as the pathogens most commonly associated with clinical infections, data on *Serratia marcescens* are inadequate and superficial.

Methods: In this study, we characterized 36 carbapenem-resistant *Serratia marcescens* (CRSM) isolates in our hospital from April 2018 to March 2019 by analysing whole-genome sequencing (WGS) data. The molecular typing of the isolates was performed using both pulsed-field gel electrophoresis (PFGE) and core genome multilocus sequence typing (cgMLST).

Results: Thirty-three of the 36 isolates showed carbapenem resistance conferred by a *bla*_{KPC-2}-harbouring plasmid, while the remaining three isolates were characterized by overexpression of beta-lactamase combined with porin loss. The *bla*_{KPC-2} genes in all the isolates were located on a plasmid of ~103 kb, except one, which was on a plasmid of ~94 kb. The gene structure surrounding *bla*_{KPC-2} in the plasmids was confirmed by integration of a partial Tn4401 structure and an intact IS26 as previously reported. Most of the plasmids also contained a mobile genetic element (MGE) comprising *qnr* and ISKpn19, which provided evidence of horizontal transfer of antibiotic resistance genes.

Conclusion: The thirty-six CRSM isolates were mainly clonally disseminated with a *bla*_{KPC-2}-harbouring plasmid in our hospital. The gene structure surrounding *bla*_{KPC-2} as an MGE, as well as the *qnr* segment, might be acquired by horizontal gene transfer, and it could aggravate the infection and increase the difficulty of clinical treatment.

Keywords: *Serratia marcescens*, carbapenem resistance, *bla*_{KPC-2}-harbouring plasmid

Introduction

Carbapenem-resistant Enterobacteriaceae are a major class of bacterial pathogens globally, but studies have focused on the organisms most commonly associated with clinical infections in the United States: *Klebsiella* spp., *Enterobacter* spp., and *Escherichia coli*.^{1,2} A report from the United States in 2014–2017 described *Serratia marcescens* as a less commonly encountered species that could also show carbapenem resistance by harbouring carbapenem resistance genes such as *bla*_{KPC-2} and *bla*_{VIM}.³ Similarly, in China, little attention has been paid to *S. marcescens*, as it is not often encountered in clinical infection. *S. marcescens* has intrinsic resistance to ampicillin and cephalosporins but not to carbapenems.⁴ However, carbapenem-resistant *S. marcescens* (CRSM) was found harbouring a plasmid-mediated *Klebsiella pneumoniae* carbapenemase (KPC), which potentially increased the complexity of clinical infections in China in 2007.^{5,6}

Correspondence: Yan Jiang; Yunsong Yu
Tel/Fax +86-571-8600-6142
Email jiangy@zju.edu.cn;
yvysl19@zju.edu.cn

As a member of Enterobacteriaceae that was first described in 1819, *S. marcescens* is a gram-negative bacillus and was initially considered a non-pathogenic organism for years. It is characterized by red pigmentation, and the function of this red pigment (prodigiosin) remains unclear because clinical isolates are rarely pigmented.⁷ In the 19th century, this species was used as a tracer organism and as a biological warfare test agent in the military and was studied in medical experiments.⁸ However, as reports of clinical infections have emerged and increased, *S. marcescens* is now thought to be an opportunistic pathogen.⁹ It is an important cause of every conceivable kind of infection, including respiratory tract infection, urinary tract infection (UTI), septicemia, meningitis, conjunctivitis, endocarditis and wound infections.^{10–16} Although *S. marcescens* displayed relatively low virulence, it caused nosocomial infections in immunocompromised patients, both adults and neonates.^{17,18}

S. marcescens often shows carbapenem resistance conferred by *bla*_{KPC}-harbouring plasmids of different types.^{5,19,20} As a result of the resistance of *S. marcescens* to most beta-lactams, clonal dissemination is aggravated, and the difficulty of clinical treatment increases. In this study, we investigated the clonal dissemination and resistance mechanism of 36 non-duplicated CRSM isolates in our hospital between April 2018 and March 2019. The whole-genome sequencing (WGS) method was used for molecular typing of isolates, which was rarely performed before analysing the structure of carbapenemase-producing plasmids. We aimed to clarify the dissemination and carbapenem resistance mechanism of *S. marcescens* in our hospital, which may contribute to clinical treatment and monitoring for infection control.

Materials and Methods

Isolate Collection

Thirty-six CRSM isolates were collected from 36 different patients in Sir Run Run Shaw Hospital, Hangzhou, from April 2018 to March 2019. Species identification was performed by MALDI-TOF mass spectrometry. All CRSM isolates were collected from various wards, including the Department of General Surgery (n=29), ICUs (n=4), the Department of Infectious Diseases (n=1), the Department of Cardiology (n=1), and the Department of Head and Neck Surgery (n=1). Three kinds of specimens were collected, namely, body fluid (n=29), sputum (n=5) and blood (n=2). Most patients were exposed to broad-spectrum antibiotics before the isolate was collected. All isolates were obtained

more than 2 days after the patients were admitted to the hospital.

Antimicrobial Susceptibility Testing

The minimal inhibitory concentrations (MICs) of the CRSM isolates were determined by the broth microdilution method. Carbapenem resistance was defined as resistance to any carbapenems, including meropenem, imipenem and ertapenem, in accordance with 2019 Clinical and Laboratory Standards Institute (CLSI) guidelines.⁴ The susceptibility of tigecycline was determined according to US Food and Drug Administration breakpoints for Enterobacteriaceae. *Escherichia coli* ATCC 25922 was used as a quality control strain. The efflux pump inhibitor test was performed as a broth microdilution experiment with or without the inhibitors in combination with meropenem.²¹

Pulsed-Field Gel Electrophoresis (PFGE)

Genomic DNA was prepared as described previously with some modifications.²² Isolated colonies were harvested from Mueller-Hinton agar plates after overnight incubation at 37°C, and the suspension was adjusted to a concentration of 10⁹ CFU/mL in cell suspension buffer (100 mM Tris-HCl, 100 mM EDTA, pH=8). After a short incubation of approximately 5–10 mins at 37°C, the bacterial suspension was mixed with an equal volume of 1% Gold Agarose (Lonza, USA) and allowed to solidify in a 100-μL plug mould. The DNA block was incubated overnight at 54°C in 1 mL of cell lysis buffer (50 mM Tris-HCl, 50 mM EDTA, 1% sarcosyl, 100 μg/mL proteinase K, pH=8). To eliminate the lysed bacterial material and inactivate proteinase K activity, the DNA blocks were washed four times at 50°C in 4 mL of Tris-EDTA buffer (100 mM Tris-HCl, 1 mM EDTA, pH=8). A slice of each plug was cut and incubated with SpeI (Takara, Japan). Restriction fragments of DNA were separated by pulsed-field gel electrophoresis (PFGE) with a CHEF MAPPER apparatus (Bio-Rad, USA) through 1% Gold Agarose. Electrophoresis was performed at 6 V/cm and 14°C. The run time was 18 h, with the pulse time ramping from 5 to 60 s. XbaI-digested DNA of *Salmonella enterica* serotype Braenderup H9812 was electrophoresed as the size marker.

Whole Genome Sequencing (WGS) and Resistance Gene Analysis

Thirty-six CRSM isolates were cultured overnight in Mueller-Hinton broth at 37°C for genomic DNA extraction

using the QIAamp DNA Mini Kit (QIAGEN, Germany). All the genomic DNAs were sequenced using paired-end 500-bp insert libraries on an Illumina HiSeq X Ten, and the resulting 150-bp Illumina reads were assembled using CLC Genomics Workbench with default settings. To obtain complete genome assemblies, five isolates (C110, 1140, 2838, 3024, and 4201) representing five clone clusters in PFGE were sequenced on the Nanopore MinIon platform. Antibiotic resistance genes were identified by resFinder3.2 (<https://cge.cbs.dtu.dk/services/ResFinder/>) with the default threshold.

Core Genome Multilocus Sequence Typing (cgMLST)

To improve the accuracy of the PFGE typing method, a local core genome multilocus sequence typing (cgMLST) scheme was established following the guide for Ridom SeqSphere+ software (<http://www.ridom.de/seqsphere/tutorials/index.shtml>). A task template of 4847 targets for cgMLST and 400 targets as accessories was established by importing assembly files of all isolates except isolates 3024 and 4201. Then, all assembly files of the 36 isolates were imported into the created database, and a comparison table was generated. Finally, a minimum spanning tree was generated by ignoring missing values.

Conjugation Experiment

After incubation for 4–6 h, NaN₃-resistant *E. coli* J53 was used as the recipient strain (100 µL) mixed with the recipient strain (100 µL), and filter mating was performed for 16–18 h at 37°C. Then, the mixture on the filter membrane was inoculated into plates containing NaN₃ (300 µg/mL, Sangon, China) supplemented with ampicillin (100 µg/mL, Sangon, China) for 24 h at 37°C. The colonies that grew on the selection plates were picked and identified by PCR and MALDI-TOF mass spectrometry.

Analysis of the Genetic Structure Surrounding *bla*_{KPC-2}

The related

*bla*_{KPC-2}-harbouring plasmids were identified by BLAST in NCBI (<https://blast.ncbi.nlm.nih.gov/Blast.cgi>). The open reading frames (ORFs) were predicted by the RAST system (<http://rast.nmpdr.org/>). The mobile genetic elements (MGEs) were determined by ISfinder (<https://www-is.biotoul.fr/blast.php>), and figures were drawn with CLC Genomics Workbench. The sequencing data for the 36 isolates have been deposited at DDBJ/ENA/

GenBank under the accession numbers WUUW000000000-WUWF000000000 and CP047679-CP047693.

Results

Dissemination and Distribution of CRSM

There were a total of 36 nonduplicated CRSM isolates collected from our hospital from April 2018 to March 2019. All isolates were divided into 5 clusters by the PFGE typing method and named from cluster A to cluster E (Figure 1A). Thirty-four of the 36 CRSM isolates were divided into clusters A, B and C with similarity values of 94.167%, 81.807% and 92.327%, respectively. There was only one isolate each in cluster D (isolate 3024) and cluster E (isolate 4201), and the similarity values of isolates 3024 and 4201 were significantly lower than those of the other three clusters. As seen in the minimum spanning tree generated by a local cgMLST scheme (Figure 1B), isolate 3024 (in green) and especially isolate 4201 (in purple) were quite distant from the other isolates, as predicted by the PFGE typing method. In addition, 4 isolates (in red box) differed from isolates C83 and C91 (in red) with no less than 14 allelic genes, similar to isolate 3024. Furthermore, the collection times of all isolates could be divided into 5 periods, which corresponded to the 5 clusters.

Upon additionally considering clinical information, 33 of the 36 isolates from the same clone were collected from the Department of General Surgery and ICU, which were the main regions of clonal dissemination and distribution. Notably, the isolate with the most significant difference in molecular typing, isolate 4201, was derived from a patient once transferred from the Department of Cardiac Surgery to the ICU after valve replacement surgery. Since it was the only case found in the ICU, we suggest that it was a special clone type that originated from the Department of Cardiac Surgery.

Antibiotic Resistance Mechanism of CRSM

All 36 CRSM isolates were highly resistant to carbapenems, including meropenem, imipenem and ertapenem, but were almost susceptible to amikacin and especially tigecycline (Table 1). PCR and a modified carbapenem inactivation method (mCIM)⁴ revealed that 33 of the 36 CRSM isolates were KPC-producing isolates. The WGS data were used to investigate the diversity of the antibiotic resistance genes carried by the 36 CRSM isolates (Table 2). It was

Figure 1 The Molecular typing of 36 carbapenem-resistant *Serratia marcescens* (CRSM) isolates by two methods. **(A)**. Pulsed-field gel electrophoresis (PFGE) typing. The isolates were divided into 5 cluster types including cluster A, B, C, D and E based on the cutoff values. **(B)**. The local ad hoc scheme of Core genome multilocus sequence typing (cgMLST). Isolates with no less than 14 different allelic genes were identified as follows: C60, 3717, 3460 and 3725 (in red boxes), 3024 (in green), 4201 (in purple).

Table 1 The MIC Distribution of 36 CRSM

Antibiotic (μg/mL)	MEM	IPM	ETP	CAZ	FOX	CTX	FEP	ATM	CIP	AK	TGC	CAV/AVI
MIC ₅₀	512	1024	512	32	512	2048	1024	>2048	16	4	1	1/4
MIC ₉₀	512	1024	1024	64	512	2048	>2048	>2048	32	8	2	2/4
MIC range	64–1024	128–1024	64–1024	8–64	64–1024	512–2048	32–>2048	128–>2048	<0.125–64	2–32	0.5–16	0.5–2/4

Abbreviations: CRSM, carbapenem-resistant *Serratia marcescens*; MIC, minimum inhibitory concentration; MEM, meropenem; IPM, imipenem; ETP, ertapenem; CAZ, ceftazidime; FOX, ceftoxitin; CTX, cefotaxime; FEP, cefepime; ATM, aztreonam; CIP, ciprofloxacin; AK, amikacin; TGC, tigecycline; CAV/AVI, ceftazidime avibactam.

Table 2 The Distribution of Antibiotic Resistance Genes in 36 CRSM Isolates

resGene(s)	Beta-Lactamases			Quinolone	Aminoglycoside		Tetracycline
	<i>bla</i> _{KPC-2}	<i>bla</i> _{CTX-M-14}	<i>bla</i> _{SRT-1} (<i>bla</i> _{SST-1})	<i>qnrS1</i> (<i>qnrD1</i>)	<i>aac</i> (3)- <i>Ild</i>	<i>aac</i> (6')- <i>Ic</i>	<i>tet</i> (41)
NO. of isolates	33	21	35(1)	34(1)	35	36	1
Location	P	C	C	P+C	C	C	C

Abbreviations: CRSM, carbapenem-resistant *Serratia marcescens*; P, plasmid; C, chromosome.

demonstrated that *bla*_{KPC-2} was the only carbapenemase gene in 33 of the isolates. In 3 carbapenem-resistant isolates without any carbapenemase genes, the outer membrane proteins ompF and ompC were not detected, while the beta-lactamases SRT-1 and CTX-M-14 were overexpressed (Supplementary Figure S1). Moreover, the efflux pump inhibitor test based on antimicrobial susceptibility testing was performed for the 36 isolates. This test demonstrated that the MICs of meropenem for most of the isolates decreased by one- or two-fold after the inhibitor was added.

Resistance to carbapenems was successfully transferred from 33 *bla*_{KPC-2}-harbouring isolates to the *E. coli* J53 recipient, except isolates C112 and 4201, by conjugation experiments. The meropenem, imipenem and ertapenem MICs of the transconjugants were in the range of 1–8 μg/mL, which indicated a slight increase compared to *E. coli* J53. Meanwhile, all transconjugants remained susceptible to amikacin and tigecycline (Table 3). In addition, the transconjugants were also resistant to ceftazidime but remained susceptible to ciprofloxacin (CIP), with a slight increase in the MIC.

General Characteristics of *bla*_{KPC-2}-Harbouring Plasmids

The *bla*_{KPC-2} gene was found in 33 isolates and localized on an ~78–104 kb plasmid by a S1 Southern blot (Supplementary Figure S2). Long-read sequencing data of five isolates were assembled, and the characteristics of the chromosomes and plasmids are listed in Table 4. Each isolate contained a large plasmid (*bla*_{KPC-2} harbouring)

Table 3 Antibiotic Susceptibilities of Transconjugants and *E. coli* J53

MIC Range (μg/mL)	31 Transconjugants	J53
MEM	1–8	<0.5
IPM	1–4	<0.25
ETP	2–8	<0.25
CAZ	8–32	<0.25
AK	4–8	4
TGC	0.25–0.5	0.25
CIP	0.125–0.5	<0.015625

Abbreviations: MIC, minimum inhibitory concentration; MEM, meropenem; IPM, imipenem; ETP, ertapenem; CAZ, ceftazidime; CIP, ciprofloxacin; AK, amikacin; TGC, tigecycline.

and a small plasmid (no resistance gene found) in addition to a chromosomal genome with a length of ~5.4 Mbp. The reads were mapped to the reference genome in CLC Genomics Workbench, and 31 *bla*_{KPC-2}-harbouring plasmids of the same size had the same sequence as the *bla*_{KPC-2}-harbouring plasmid from isolate C110 (subsequently named pC110-KPC), which was 103.167 kb in size. The *bla*_{KPC-2}-harbouring plasmids from isolate 3024 and isolate 4201 (subsequently named p3024-KPC and p4201-KPC) had lengths of 103.175 kb and 94.056 kb, respectively.

pC110-KPC was a closed circular DNA with a size of 103167 bp and belonged to incompatibility group F. It contained 138 predicted ORFs with an average G+C content of 54.2%. A BLAST search in NCBI revealed that plasmid pC110-KPC shares high identity with the previously reported IncF plasmids pSZF_KPC (accession no. MH917122.1)²³ and p628-KPC (accession no. KP987218.1),²⁴ both of

Table 4 Characteristics of the Nanopore-Sequenced Genome Assembly of Five CRSM

Isolates	Genome		Plasmid 1			Plasmid 2		
	Length (bp)	resGene	Length (bp)	Replicon	resGene	Length (bp)	Replicon	resGene
C110	5427741	<i>bla</i> _{CTX-M-14} , <i>bla</i> _{SRT-1} , <i>qnrS1</i> , <i>aac</i> (3)- <i>lid</i> , <i>aac</i> (6')- <i>Ic</i>	103167	—	<i>qnrS1</i> , <i>bla</i> _{KPC-2}	2953	—	—
1140	5429004	<i>bla</i> _{CTX-M-14} , <i>bla</i> _{SRT-1} , <i>qnrS1</i> , <i>aac</i> (3)- <i>lid</i> , <i>aac</i> (6')- <i>Ic</i>	103167	—	<i>qnrS1</i> , <i>bla</i> _{KPC-2}	2953	—	—
2838	5416416	<i>bla</i> _{SRT-1} , <i>qnrS1</i> , <i>aac</i> (3)- <i>lid</i> , <i>aac</i> (6')- <i>Ic</i>	103167	—	<i>qnrS1</i> , <i>bla</i> _{KPC-2}	2953	—	—
3024	5428813	<i>bla</i> _{CTX-M-14} , <i>bla</i> _{SRT-1} , <i>qnrS1</i> , <i>aac</i> (3)- <i>lid</i> , <i>aac</i> (6')- <i>Ic</i>	103175	—	<i>qnrS1</i> , <i>bla</i> _{KPC-2}	2953	—	—
4201	5331789	<i>bla</i> _{SRT-1} , <i>aac</i> (6')- <i>Ic</i> , <i>tet</i> (41)	94056	—	<i>bla</i> _{KPC-2}	2953	—	—

Abbreviations: CRSM, carbapenem-resistant *Serratia marcescens*, bp, base pair; —, not found by plasmidFinder and resFinder on CGE website.

which were from a *K. pneumoniae* isolate found in China, with 94% query coverage and >99% nucleotide identity (Figure 2A). The *bla*_{KPC-2}-harbouring plasmids from isolates 1140 and 2838 were exactly the same as pC110-KPC. Plasmid p3024-KPC was 8 bp longer than pC110-KPC as a result of a short base segment (TATCTTGT) inserted into position 2476–2477 of pC110-KPC. Plasmid p4201-KPC was 94056 bp in length and contained 122 predicted ORFs with an average G+C content of 53.1%. It was similar (95% query coverage and >99% nucleotide identity) to pHS091147 (accession no. KX236178.1)²⁵ from a *K. pneumoniae* isolate found in China (Figure 2B).

Genetic Environment of the *bla*_{KPC-2} Gene

All *bla*_{KPC-2}-harbouring plasmids in this study belonged to the non-Tn4401 structure type, which was defined as *bla*_{KPC}-bearing non-Tn4401 elements (NTE_{KPC}) as previously reported.²⁶ In fact, the surrounding structure of *bla*_{KPC-2} was considered to result from the integration of a partial Tn4401 structure and an intact IS26. The ORFs are ordered as follows (Figure 3): IS26, Tn3-resolvase, ISKpn27, the *bla*_{KPC-2} gene, and the ISKpn6-like element. This structure was the same as that in plasmid pKPHS2 (accession no. CP003224),²⁷ except for a point mutation (C→T) (Figure 3). Plasmid pKPHS2 was from a *K. pneumoniae* isolate and had

Figure 2 The circular maps of pC110-KPC and p4201-KPC. (A). The circle in yellow represented plasmid pC110-KPC, in orange represented pSZF_KPC, in red represented p628-KPC. (B). The circle in purple represented p4201-KPC, in blue represented pHS091157. The peak map in (A) and (B) represented the GC content of plasmid pC110-KPC and p4201-KPC respectively. Arcs in grey indicate the position of *bla*_{KPC} and *bla*_{qnr} in plasmids pC110-KPC and p4201-KPC. The maps were created by Brig v0.95.

Figure 3 A schematic diagram of the genetic structure surrounding *bla*_{KPC-2}. The genetic structure surrounding *bla*_{KPC-2} in the plasmid pC110-KPC represented all plasmids harbouring *bla*_{KPC-2} in this study. The positions indicated by orange lines are the point mutation positions at which C and T are in plasmids pC110-KPC and pKPHS2, respectively. The direction of the arrow represents the direction of transcription.

a similar backbone as another *K. pneumoniae* plasmid, pKP048 (accession no. FJ628167),²⁸ and both of these plasmids were found in China. The surrounding structure of *bla*_{KPC-2} in plasmid pKP048 lacked IS26 with an incomplete *tnpR* gene compared to plasmid pC110-KPC, which we considered to be a result of gene recombination.

Coexistence of the Quinolone Resistance Gene *qnrS1* with *bla*_{KPC-2}

Other types of resistance genes were identified from the genome sequences, including *bla*_{CTX-M-14}, *bla*_{SRT-1} (*bla*_{SST-1}), *qnrS1* (*qnrD1*), *aac*(3)-*IId*, *aac*(6')-*Ic*, and *tet*(41), among which *qnrS1* was the only resistance gene located on a *bla*_{KPC-2}-harbouring plasmid (Table 2). There was an ~6-kb region comprising a quinolone resistance gene (*qnrS1*) and an intact *ISKpn19* ~8 kb downstream of *bla*_{KPC-2} on plasmids (Figure S3). In addition, gene *qnrS1* was also located in the chromosome of most isolates.

Discussion

Carbapenem-resistant *S. marcescens* strains are distributed and disseminated globally, and the positivity rate has increased since China has been the epidemic region for carbapenem-resistant Enterobacteriaceae (CRE). Several studies on the clonal dissemination of *S. marcescens* were previously reported.^{17,29,30} However, this was the first study that utilized WGS to gain insight into antibiotic resistance genes and MGEs in CRSM isolated from different patients in China.

WGS has emerged as an ultimate typing tool suitable for any bacterial species, study type, and laboratory.³¹ cgMLST has been proposed as a very useful and practical method based on WGS to distinguish isolates within epidemic settings and

between epidemic and unrelated specimens.³² As there was no public database of cgMLST for *S. marcescens*, we established a local cgMLST scheme using Ridom SeqSphere software. By cgMLST, four isolates were distinguished from PFGE typing. The results of cgMLST differed from those of PFGE typing, which improved the accuracy of molecular typing and was attributed to the high sensitivity of cgMLST.

It was reported³³ that the mechanisms of beta-lactam resistance in *S. marcescens* include the production of beta-lactamases, diminished outer membrane permeability, modification of the target penicillin-binding proteins (PBPs), overexpression of active efflux systems, synthesis of aminoglycoside-modifying enzymes, and structural alteration of the GyrA protein. The mechanism of carbapenem resistance in the CRSM isolates was divided into four types:³⁴ carbapenemase production, functional efflux pump systems, diminished permeability of the outer membrane and alteration of PBP targets. Since carbapenemase production was the dominant type referred to in most in related reports,^{29,30,35} KPC production was the most frequent type observed in our study. The resistance mechanism of the efflux pump in 3 isolates without *bla*_{KPC-2} did not play the main role. In addition, we also evaluated the outer membrane porins (*ompF* and *ompC*), which are related to antimicrobial resistance. Based on the results (Figure S1) and a previous report,³⁶ it was suggested that the carbapenem resistance of the 3 isolates without *bla*_{KPC-2} was predominantly mediated by the overexpression of SRT-1 and CTX-M-14 combined with porin loss.

In China, *S. marcescens*-harboured *bla*_{KPC-2} was first described on a conjugative plasmid in 2007, and since then, related reports have emerged. The sizes of plasmids harbouring *bla*_{KPC-2} in *S. marcescens* varied from 50 kb to 118 kb, and the plasmid types were IncF, IncK, IncL/M and IncX, most of which were conjugative.^{19,20,23,29} In this

study, we found that most of the plasmids were ~103 kb in length and belonged to the IncF incompatibility group, which was not previously reported. Through WGS analysis against the NCBI database, we hypothesized that all of the plasmids were derived from *K. pneumoniae* isolates in China. All of the *bla*_{KPC-2}-harbouring plasmids were successfully transferred except plasmids from isolates C112 and 4201. The carbapenem MICs of the transconjugants increased but not significantly, probably because of the low copy numbers of the plasmids. The slight increase in the CIP MIC was due to the *qnrS* gene carried by the *bla*_{KPC-2}-harbouring plasmids.

Since *bla*_{KPC-2} could be transferred frequently either by plasmids or by integrative and conjugative elements (ICEs) and insertion elements (ISs), confirming the genetic structure surrounding *bla*_{KPC-2} can contribute to monitoring the horizontal transfer of *bla*_{KPC-2} and the evolution process of *bla*_{KPC-2}-harbouring plasmids. The most common *bla*_{KPC-2}-containing mobile element is a Tn3-based transposon, Tn4401. All CRSM isolates harbouring *bla*_{KPC-2} in this study possessed the same structure surrounding the *bla*_{KPC-2} gene as pC110-KPC, as shown in Figure 3. This structure was defined as the NTE_{KPC}-Ib group, which was represented by plasmid pKPHS2.²⁶ There was only one base difference between pC110-KPC and pKPHS2. Based on the timeline, it was suggested that the former was probably derived from the latter by point mutation.

As WGS showed, *qnrS1* was the only resistance gene located on the *bla*_{KPC-2}-harbouring plasmids. The *qnrS1*-harbouring segment was widely distributed in plasmids from *K. pneumoniae*; however, this segment did not occur in plasmid p4201-KPC or in plasmids pSZF_KPC and p628-KPC. The combination of the similar genes *qnrS1* and *ISKpn19* was also found in *E. coli* as previously reported.³⁷ It was indicated that the segment could have been transferred among *bla*_{KPC-2}-harbouring plasmids and chromosomes from different strains, and this was probably the way the multi-resistant plasmid evolved.

All isolates collected in this study were confirmed to be resistant to most beta-lactams, including carbapenems, but were susceptible to tigecycline and amikacin (Table 1). Although most of the patients with CRSM could not be clearly diagnosed with infection or colonization by CRSM because of the complex clinical situation, they recovered after administration of tigecycline and amikacin, which were often combined with beta-lactams. Furthermore, all isolates were susceptible to ceftazidime avibactam (CAZ/AVI), as determined by the broth microdilution method,

which provides a strong possibility of combination therapy as previously reported.^{38,39}

Characterization of the dissemination and carbapenem resistance mechanism of *S. marcescens* in our hospital showed that there were still some limitations in this study. All isolates were collected from the patients of a single center and none was collected from the ward environment in the hospital, so the sample size was limited for a more detailed investigation. Because a public MLST or cgMLST database has not been established to date, the isolates in our study cannot be officially defined and compared among different laboratories.

Conclusion

In this study, CRSM isolates were mainly clonally disseminated with a *bla*_{KPC-2}-harbouring plasmid in a nosocomial environment. The gene structure surrounding *bla*_{KPC-2}, as well as the *qnr* segment, might be acquired by horizontal gene transfer, and it could aggravate the infection and increase the difficulty of clinical treatment. Since MGEs containing carbapenem resistance genes are commonly associated with horizontal gene transfer, further study is required.

Ethics Approval

The collection of CRSM was part of the routine hospital laboratory procedure.

Funding

This work was supported by the National Natural Science Foundation of China (grant number 81830069) and the Key Research and Development Programme of Zhejiang (grant number 2015C03046).

Disclosure

The authors report no conflicts of interest associated with this work.

References

1. Guh AY, Bulens SN, Mu Y, et al. Epidemiology of carbapenem-resistant *Enterobacteriaceae* in 7 US communities, 2012–2013. *JAMA*. 2015;314(14):1479–1487. doi:10.1001/jama.2015.12480
2. Weiner LM, Webb AK, Limbago B, et al. Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the national healthcare safety network at the centers for disease control and prevention, 2011–2014. *Infect Control Hosp Epidemiol*. 2016;37(11):1288–1301. doi:10.1017/ice.2016.174
3. Walters MS, Witwer M, Lee Y-K, et al. Carbapenemase-producing carbapenem-resistant *Enterobacteriaceae* from less common *Enterobacteriaceae* Genera — United States, 2014–2017. *MMWR Morb Mortal Wkly Rep*. 2018;67(23):668–669. doi:10.15585/mmwr.mm6723a4

4. Clinical and Laboratory Standards Institute. *Performance Standards for Antimicrobial Susceptibility Testing*. 29th. CLSI supplement M100. Wayne, PA: CLSI; 2019
5. Zhang R, Zhou HW, Cai JC, et al. Plasmid-mediated carbapenem-hydrolysing β -lactamase KPC-2 in carbapenem-resistant *Serratia marcescens* isolates from Hangzhou, China. *J Antimicrob Chemother*. 2007;59(3):574–576. doi:10.1093/jac/dk1541
6. Cai JC, Zhou HW, Zhang R, et al. Emergence of *Serratia marcescens*, *Klebsiella pneumoniae*, and *Escherichia coli* isolates possessing the plasmid-mediated carbapenem-hydrolyzing beta-lactamase KPC-2 in intensive care units of a Chinese hospital. *Antimicrob Agents Chemother*. 2008;52(6):2014–2018. doi:10.1128/AAC.01539-07
7. Hejazi A, Falkiner FR. *Serratia marcescens*. *J Med Microbiol*. 1997;46(11):903–912. doi:10.1099/00222615-46-11-903
8. Mahlen SD. *Serratia* infections: from military experiments to current practice. *Clin Microbiol Rev*. 2011;24(4):755–+. doi:10.1128/cmr.00017-11
9. Yokota M, Okazawa A, Tanaka T. *Serratia marcescens* as an opportunistic human pathogen. *Nihon saikingaku zasshi. Jpn J Bacteriol*. 2001;56(3):527–535. doi:10.3412/jsb.56.527
10. Sakai S, Nishio A, Kumamoto Y. [Clinical studies on urinary tract infections caused by *Serratia marcescens*. II. Epidemiological studies on onset of *Serratia marcescens* urinary tract infections in the urological ward]. *Jpn j Urol*. 1983;74(4):485–502. doi:10.5980/jpnjuro1928.74.4_485. Japanese.
11. Theccanat G, Hirschfield L, Isenberg H. *SERRATIA-MARCESCENS* MENINGITIS. *J Clin Microbiol*. 1991;29(4):822–823. doi:10.1128/JCM.29.4.822-823.1991
12. Hogman CF, Fritz H, Sandberg L. Posttransfusion *Serratia-Marcescens* Septicemia. *Transfusion*. 1993;33(3):189–191. doi:10.1046/j.1537-2995.1993.33393174441.x
13. Byrne AH, Boyle B, Herra CM, et al. *Serratia marcescens* causing hospital-acquired lower respiratory tract infection. *J Hosp Infect*. 2000;45(3):242–244. doi:10.1053/jhin.2000.0761
14. Pak KY, Kim SI, Lee JS. Neonatal bacterial conjunctivitis in Korea in the 21st century. *Cornea*. 2017;36(4):415–418. doi:10.1097/ICO.0000000000001122
15. Us E, Kutlu HH, Tekeli A, et al. Wound and soft tissue infections of *Serratia marcescens* in patients receiving wound care: a health care-associated outbreak. *Am J Infect Control*. 2017;45(4):443–447. doi:10.1016/j.ajic.2016.11.015
16. Schechter MC, Spicer JO, Del Mar Aldrete S, et al. *Serratia marcescens* infectious endocarditis: injection drug use, left-sided heart disease, and poor outcomes. *Infect Dis Clin Pract*. 2018;26(4):216–219. doi:10.1097/IPC.0000000000000614
17. Dessi A, Puddu M, Testa M, et al. *Serratia marcescens* infections and outbreaks in neonatal intensive care units. *J Chemother*. 2009;21(5):493–499. doi:10.1179/joc.2009.21.5.493
18. Ruiz-Sada P, Escalante M, Lizarralde E. Severe acute infection due to *Serratia marcescens* causing respiratory distress in an immunocompetent adult. *Rom J Intern Med*. 2016;54(2):134–136. doi:10.1515/rjim-2016-0013
19. Bryant KA, Van Schooneveld TC, Thapa I, et al. KPC-4 is encoded within a truncated Tn4401 in an IncL/M plasmid, pNE1280, isolated from *Enterobacter cloacae* and *Serratia marcescens*. *Antimicrob Agents Chemother*. 2013;57(1):37–41. doi:10.1128/AAC.01062-12
20. Gona F, Caio C, Iannolo G, et al. Detection of the IncX3 plasmid carrying bla(KPC-3) in a *Serratia marcescens* strain isolated from a kidney–liver transplanted patient. *J Med Microbiol*. 2017;66(10):1454–1456. doi:10.1099/jmm.0.000592
21. Kern WV, Steinke P, Schumacher A, et al. Effect of 1-(1-naphthylmethyl)-piperazine, a novel putative efflux pump inhibitor, on antimicrobial drug susceptibility in clinical isolates of *Escherichia coli*. *J Antimicrob Chemother*. 2006;57(2):339–343. doi:10.1093/jac/dki445
22. Ligozzi M, Fontana R, Aldegheri M, et al. Comparative evaluation of an automated repetitive-sequence-based PCR instrument versus pulsed-field gel electrophoresis in the setting of a *Serratia marcescens* nosocomial infection outbreak. *J Clin Microbiol*. 2010;48(5):1690–1695. doi:10.1128/JCM.01528-09
23. Miao M, Wen H, Xu P, et al. Genetic diversity of carbapenem-resistant *Enterobacteriaceae* (CRE) clinical isolates from a tertiary hospital in Eastern China. *Front Microbiol*. 2019;9. doi:10.3389/fmicb.2018.03341
24. Wang L, Fang H, Feng J, et al. Complete sequences of KPC-2-encoding plasmid p628-KPC and CTX-M-55-encoding p628-CTXM coexisted in *Klebsiella pneumoniae*. *Front Microbiol*. 2015;6. doi:10.3389/fmicb.2015.00838
25. Tang Y, Shen P, Liang W, et al. A putative multi-replicon plasmid co-harboring beta-lactamase genes bla(KPC-2), bla(CTX-M-14) and bla(TEM-1) and trimethoprim resistance gene dfrA25 from a *Klebsiella pneumoniae* sequence type (ST) 11 strain in China. *PLoS One*. 2017;12(2). doi:10.1371/journal.pone.0186097.
26. Chen L, Mathema B, Chavda KD, et al. Carbapenemase-producing *Klebsiella pneumoniae*: molecular and genetic decoding. *Trends Microbiol*. 2014;22(12):686–696. doi:10.1016/j.tim.2014.09.003
27. Liu P, Li P, Jiang X, et al. Complete genome sequence of *Klebsiella pneumoniae* subsp pneumoniae HS11286, a multidrug-resistant strain isolated from human sputum. *J Bacteriol*. 2012;194(7):1841–1842. doi:10.1128/JB.00043-12
28. Jiang Y, Yu D, Wei Z, et al. Complete nucleotide sequence of *Klebsiella pneumoniae* multidrug resistance plasmid pKP048, carrying bla(KPC-2), bla(DHA-1), qnrB4, and armA. *Antimicrob Agents Chemother*. 2010;54(9):3967–3969. doi:10.1128/AAC.00137-10
29. da Costa Guimaraes AC, Almeida ACS, Nicoletti AG, et al. Clonal spread of carbapenem-resistant *Serratia marcescens* isolates sharing an IncK plasmid containing bla(KPC-2). *Int J Antimicrob Agents*. 2013;42(4):369–370. doi:10.1016/j.ijantimicag.2013.05.017
30. Rodriguez C, Brengi S, Cáceres MA, et al. Polyclonal dissemination of KPC-2 in *Serratia marcescens*, including a clone with epidemic behaviour in the nosocomial niche. *Int J Antimicrob Agents*. 2017;49(5):657–658. doi:10.1016/j.ijantimicag.2017.03.003
31. Kluytmans-van den Bergh MFQ, Rossen JWA, Bruijning-Verhagen PCJ, et al. Whole-genome multilocus sequence typing of extended-spectrum-beta-lactamase-producing *Enterobacteriaceae*. *J Clin Microbiol*. 2016;54(12):2919–2927. doi:10.1128/JCM.01648-16
32. Liu -Y-Y, Chen -C-C, Chiou C-S. Construction of a pan-genome allele database of *Salmonella enterica* serovar enteritidis for molecular subtyping and disease cluster identification. *Front Microbiol*. 2016;7. doi:10.3389/fmicb.2016.02010
33. Yang H, Cheng J, Hu L, et al. Mechanisms of antimicrobial resistance in *Serratia marcescens*. *Afr J Microbiol Res*. 2012;6(21):4427–4437. doi:10.5897/AJMR11.1545
34. Sun Y, Zhang H, Liu J, et al. The mechanism of carbapenems resistance in *Serratia marcescens* strains. *Chin J Microbiol Immunol*. 2014;34(10):774–779.
35. Guo P, Qiao Y, Zhang H, et al. Profile and mechanism of imipenem resistance in clinical isolates of *Serratia marcescens*. *Chin J Infect Chemother*. 2017;17(2):187–191.
36. Suh B, Bae IK, Kim J, et al. Outbreak of meropenem-resistant *Serratia marcescens* mediated by chromosomal AmpC beta-Lactamase overproduction and outer membrane protein loss. *Antimicrob Agents Chemother*. 2010;54(12):5057–5061. doi:10.1128/AAC.00768-10
37. Liu X-Q, Wang J, Li W, et al. Distribution of cfr in *Staphylococcus spp.* and *Escherichia coli* strains from pig farms in China and Characterization of a Novel cfr-Carrying F43: A-: B-Plasmid. *Front Microbiol*. 2017;8:329. doi:10.3389/fmicb.2017.00329

38. Rodriguez C, Brengi S, Cáceres MA, et al. Successful management with fosfomycin + ceftazidime of an infection caused by multiple highly-related subtypes of multidrug-resistant and extensively drug-resistant KPC-producing *Serratia marcescens*. *Int J Antimicrob Agents*. 2018;52(5):737–739. doi:10.1016/j.ijantimicag.2018.07.020
39. Gaudereto JJ, Perdigão Neto LV, Leite GC, et al. Synergistic effect of ceftazidime-avibactam with meropenem against panresistant, carbapenemase-harboring *Acinetobacter baumannii* and *Serratia marcescens* investigated using time-kill and disk approximation assays. *Antimicrob Agents Chemother*. 2019;63(5). doi:10.1128/AAC.02367-18.

Infection and Drug Resistance

Dovepress

Publish your work in this journal

Infection and Drug Resistance is an international, peer-reviewed open-access journal that focuses on the optimal treatment of infection (bacterial, fungal and viral) and the development and institution of preventive strategies to minimize the development and spread of resistance. The journal is specifically concerned with the epidemiology of

antibiotic resistance and the mechanisms of resistance development and diffusion in both hospitals and the community. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/infection-and-drug-resistance-journal>